Posts for Ticker ‘IDMI’

Many Biotechs Barely On Life Support (BPAX, CEGE, EPIX, IDMI, LJPC, NRGN, NFLD, TPTX)

Burning Money PicWe have run a watch list of companies under their own strategic review, and the number of biotech (or grouped with biotech) stocks under this description is just staggering.   We published a full review of this over at BioHealthInvestor.com.  The list includes Biosante Pharmaceuticals, Inc. (NASDAQ: BPAX), Cell Genesys, Inc. (NASDAQ: CEGE), EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), IDM Pharma, Inc. (NASDAQ: IDMI), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), Neurogen Corporation (NASDAQ: NRGN), Northfield Laboratories Inc. (NASDAQ: NFLD) and TorreyPines Therapeutics, Inc. (NASDAQ: TPTX) are all under strategic reviews and their futures are probably questionable at best.

You can read that full report here at the BioHealthInvestor.com website.

Jon C. Ogg
May 13, 2009

Posted on: May 13, 2009 – 11:31 am in Accounting, Biotech, Drug companies, FDA, Medical, Mergers and Buy Outs, Pharmaceuticals, Trading Alert, , , , , , , ,

Major Biotech Movers (AGEN, CEGE, ENCY, IDMI, IMCL, ONXX, PFE, NTII, OXGN, PSDV, SIRT)

Antigenics Inc.  (NASDAQ: AGEN) A study for Cancer vaccine, Oncophage, for the treatment of metastatic melanoma showed mixed results this morning. Shares are down almost 7% to $2.17. The 52 week range is $1.54 to $5.42.

Cell Genesys, Inc. (NASDAQ: CEGE). Shares continue to climb following report Friday citing that vaccine candidate GCAX showed immune response in prostate cancer patients. Shares are trading at $2.93 in mid-day trading. The 52 week range is $1.78 to $7.30.

IDM Pharma, Inc. (NASDAQ: IDMI). Downgraded by Rodman & Renshaw. Shares plummet over 18% to $2.57. The 52 week range is $0.57 to $10.75.

Imclone Pharmaceuticals (NASDAQ: IMCL). Halted testing for competitor Onyx Pharmaceuticals (NASDAQ: ONXX) in the lung cancer drug market and a 4.96% stake purchase by Steve Cohen’s hedge fund, SAC Capital, pushed Imclone up early Tuesday. Shares have returned down to $38.41 in mid-day trading. The 52 week range is $27.50 to $47.94

Neurobiological Technologies Inc. (NASDAQ: NTII) Received a $2.1 million quarterly royalty payment for sales of Memantine, a moderate-to-severe Alzheimer’s disease treatment, from Merz Pharmaceuticals GmbH. Shares have showed little reaction, trading at $2.67. The 52 week range is $2.06 to $19.53.

Oxigene Inc. (NASDAQ: OXGN) Secures $40 million committed equity financing facility. Shares are down over 3% and trading in at $2.05 with a 52 week range of $2.01 to $5.12.

Onyx Pharmaceuticals (NASDAQ: ONXX). Shares are down by $3.47 to $29.62, a 10% drop after being murdered yesterday due to a Phase III testing halt for its lung cancer drug Nexavar. Shares fell almost 25% yesterday. The 52 week range is $23.65 to $61.18.

Today, Pfizer (NYSE: PFE) announced offer to buy all issued and outstanding shares of Encysive Pharmaceuticals (NASDAQ: ENCY) for $2.35 per share, a transaction valued at $195 million in equity. Pfizer will acquire the rights to THELIN, a treatment for PAH currently in pre-Phase III clinical testing in the United States. Pfizer is up almost $0.10 to $22.45 in mid-day trading. The range is $21.56 to $27.73. Encysive is up 110% to $2.27. The 52 week range is $0.59 to $5.02.

Psivida Ltd.  (NASDAQ: PSDV)  Received first R&D payments from Pfizer of $500,000 in part of an over $160 million agreement. Shares are down over 2% at $0.78. The 52 week range is $0.39 to $2.99.

Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT). Co-founder to present first In-Vivo, pre-clinical data showing SIRT1 activation has the ability to suppress tumor formation in cancer of the intestine and colon. Shares are down trading at $11.59 with a 52 week range of $9.81 to $21.99.

Rachel Lopez
February 20, 2008

Posted on: February 20, 2008 – 1:13 pm in Biotech, , , , , , , , , , ,

Unusual Biotech Movers (DSCO, GNTA, IDMI, DDSS, POTP, DARA)

Discovery Laboratories Inc. (NASDAQ: DSCO) shares are up after a report that their drug Surfaxin, a respiratory distress syndrome treatment for premature infants, should gain FDA approval by May. In pre-market trading, the shares rose 6% to $2.08. Since opening, shares are up almost 13% to $2.21 in mid-morning trading. The 52 week range is $1.75 to $3.75.

Genta Incorporated (NASDAQ: GNTA) shares are down over 22% to $0.53 per share after news this morning that they have entered into an agreement to sell 6 million shares of common stock to institutional investors for $3.1 million in proceeds.

IDM Pharma, Inc. (NASDAQ: IDMI) shares are recovering today after last week’s plunge due to a delisting threat from the Nasdaq Stock Market. The company has until August 4, 2008 to close at over $1 for 10 consecutive days. Shares are up over 30% this morning to $2.20. The 52 week range is $0.57 to $10.75.

Labopharm Inc. (NASDAQ: DDSS) shares continue to rise after Friday’s announcement that late-stage clinical trials for Trazodone once-daily antidepressant showed improvement in patients’ quality of sleep. The drug has FDA approval for a twice-daily treatment and the company expects to apply for the FDA approval of the once-daily version later this year. Shares are up over 15% in early morning trading to $2.68.

Stockholder approval for Point Therapeutics, Inc. (NASDAQ: POTP) pending merger with DARA BioSciences, Inc. is expected this afternoon. Assuming the merger closes February 12 as expected, the new entity will trade under “DARA” on Nasdaq. Shares rose up over $0.06 in early morning trading but have slipped back down to opening price ranges to $0.14 in mid-day trading on relatively high trading volume.

Rachel Lopez
February 11, 2008

Posted on: February 11, 2008 – 10:59 am in Biotech, , , , , ,